Abstract
RNA encoding the human serotonin 5-HT2C receptor (5-HT2CR) undergoes adenosine-to-inosine RNA editing events at five positions, resulting in an alteration of amino acids in the second intracellular loop. Several edited 5-HT2CRs possess a reduced G-protein coupling efficiency compared to the completely non-edited isoform. The current studies show that the efficacy of the hallucinogenic drug lysergic acid diethylamide and of antipsychotic drugs is regulated by RNA editing, suggesting that alterations in editing efficiencies or patterns might result in the generation of a 5-HT2CR population differentially responsive to serotonergic drugs. An examination of the efficiencies of RNA editing of the 5-HT2CR in prefrontal cortex of control individuals vs. subjects diagnosed with schizophrenia or major depressive disorder revealed no significant differences in RNA editing among the three populations. However, subjects who had committed suicide (regardless of diagnosis) exhibited a statistically significant elevation of editing at the A-site, which is predicted to change the amino acid sequence in the second intracellular loop of the 5-HT2CR. These findings suggest that alterations in RNA editing may contribute to or complicate therapy in certain psychiatric disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Almaula N, Ebersole BJ, Zhang D, Weinstein H, Sealfon SC . (1996): Mapping the binding site pocket of the serotonin 5-hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem 271: 14672–14675
Arora KK, Sakai A, Catt KJ . (1995): Effects of second intracellular loop mutations on signal transduction, internalization of the gonadotropin-releasing hormone receptor. J Biol Chem 270: 22820–22826
Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, Chi L, Millar RP, Davidson JS, Weinstein H, Sealfon SC . (1998): Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem 273: 10445–10453
Barker EL, Westphal RS, Schmidt D, Sanders-Bush E . (1994): Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269: 11687–11690
Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP . (1999): Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 55: 863–872
Blin N, Yun J, Wess J . (1995): Mapping of single amino acid residues required for selective activation of Gq/11 by the m3 muscarinic acetylcholine receptor. J Biol Chem 270: 17741–17748
Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB . (1997): Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387: 303–308
Burris KD, Breeding M, Sanders-Bush E . (1991): (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther 258: 891–896
Cheng Y, Prusoff WH . (1973): Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108
Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M . (1998): Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) 136: 409–414
Endicott J, Spitzer RL . (1978): A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35: 837–844
Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR . (1999): Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 21: 82S–90S
Glazer WM . (1999): Does loxapine have “atypical” properties? Clinical evidence. J Clin Psychiatry 60: 42–46
Herrick-Davis K, Grinde E, Niswender CM . (1999): Serotonin 5-HT2C Receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. Neurochemistry 73: 1711–1717
Herrick-Davis K, Egan C, Teitler M . (1997): Activating mutations of the serotonin 5-HT2C receptor. J Neurochem 69: 1138–1144
Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S . (1998): 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 7: 1507–1509
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP . (1994): International Union of Pharmacology classification of receptors for 5- hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157–203
Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, Meltzer HY, Overholser JC, Stockmeier CA . (1998): Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J Neurochem 70: 763–771
Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP . (1997): SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36: 609–620
Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D . (1995): Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics 27: 274–279
Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Kohler C, Delf AM . (1998): 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913–924
Meltzer HY, Jayathilake K . (1999): Low-dose loxapine in the treatment of schizophrenia: is it more effective and more “atypical” than standard-dose loxapine? J Clin Psychiatry 60: 47–51
Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA . (1996): Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl) 124: 176–187
Meltzer HY, Matsubara S, Lee JC . (1989): The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390–392
Milligan G, Bond RA, Lee M . (1995): Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16: 10–13
Moreau JL, Bos M, Jenck F, Martin JR, Mortas P, Wichmann J . (1996): 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 6: 169–175
Moro O, Lameh J, Hogger P, Sadee W . (1993): Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. J Biol Chem 268: 22273–22276
Newton RA, Phipps SL, Flanigan TP, Newberry NR, Carey JE, Kumar C, McDonald B, Chen C, Elliott JM . (1996): Characterization of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. J Neurochem 67: 2521–2531
Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E . (1999): RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274: 9472–9478
Roth BL, Meltzer HY . (1995): The Role of Serotonin in Schizophrenia. In: Bloom FE, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press Ltd. pp 1215–1227 (Ch. 102).
Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S . (1991): Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem Biophys Res Commun 181: 1469–1478
Samama P, Cotecchia S, Costa T, Lefkowitz RJ . (1993): A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625–4636
Sanders-Bush E, Canton H . (1995): Serotonin Receptors: Signal Transduction Pathways. New York, Raven Press
Segman RH, Ebstein RP, Heresco-Levy U, Gorfine M, Avnon M, Gur E, Nemanov L, Lerer B . (1997): Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatr Genet 7: 75–78
Simpson L, Emeson RB . (1996): RNA editing. Ann Rev Neurosci 19: 27–52
Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY . (1997): Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16: 162–173
Verrall S, Ishii M, Chen M, Wang L, Tram T, Coughlin SR . (1997): The thrombin receptor second cytoplasmic loop confers coupling to Gq-like G proteins in chimeric receptors. Additional evidence for a common transmembrane signaling and G protein coupling mechanism in G protein-coupled receptors. J Biol Chem 272: 6898–6902
Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M . (1997): Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 54: 49–55
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J . (1997): Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357–372
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D . (1998): Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897–3902
Westphal RS, Sanders-Bush E . (1994): Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 46: 937–942
Xie E, Zhu L, Zhao L, Chang LS . (1996): The human serotonin 5-HT-2C receptor complete cDNA, genomic structure and alternatively spliced variant. Genomics 35: 551–561
Acknowledgements
This research was supported by a postdoctoral fellowship from the Pharmaceutical Research and Manufacturers of America Foundation (C.M.N.) and National Institutes of Health research grants NS35891 (R.B.E.), MH57019 (K.H.D.), MH45488 (C.A.S.), MH 34007 (E.S.B.) and The American Foundation for Suicide Prevention. The authors acknowledge the assistance of Bryan L. Roth, M.D., Ph.D., in the psychiatric evaluation of three subjects and Elizabeth Balraj, in the Cuyahoga County Coroner's Office.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niswender, C., Herrick-Davis, K., Dilley, G. et al. RNA Editing of the Human Serotonin 5-HT2C Receptor: Alterations in Suicide and Implications for Serotonergic Pharmacotherapy. Neuropsychopharmacol 24, 478–491 (2001). https://doi.org/10.1016/S0893-133X(00)00223-2
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(00)00223-2
Keywords
This article is cited by
-
Ethanol deprivation and central 5-HT deficiency differentially affect the mRNA editing of the 5-HT2C receptor in the mouse brain
Pharmacological Reports (2023)
-
Serotonin 5-HT2C Receptor Cys23Ser Single Nucleotide Polymorphism Associates with Receptor Function and Localization In Vitro
Scientific Reports (2019)
-
A-to-I RNA editing in the rat brain is age-dependent, region-specific and sensitive to environmental stress across generations
BMC Genomics (2018)
-
The role of 5-HT receptors in depression
Molecular Brain (2017)
-
ADAR RNA editing in human disease; more to it than meets the I
Human Genetics (2017)
